Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Abdominal Cancer
Interventions
PROCEDURE

Intervention: MRI-Linac SABR

The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.

Trial Locations (2)

2010

RECRUITING

GenesisCare - St Vincent's Sydney, Darlinghurst

3084

NOT_YET_RECRUITING

Austin Health, Melbourne

All Listed Sponsors
collaborator

Trans Tasman Radiation Oncology Group

OTHER

lead

Australasian Gastro-Intestinal Trials Group

NETWORK

NCT06604533 - Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer | Biotech Hunter | Biotech Hunter